(Q36597431)

15 August 2017

1 reference

title

New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage (English)

1 reference

15 August 2017

Eleftherios Mylonakis

series ordinal

3

object named as

Eleftherios Mylonakis

1 reference

15 August 2017

Elias K Spanakis

1

1 reference

PubMed ID

16983621

15 August 2017

George Aperis

series ordinal

2

1 reference

PubMed ID

16983621

15 August 2017

language of work or name

English

0 references

publication date

8 September 2006

1 reference

Clinical Infectious Diseases

15 August 2017

1 reference

15 August 2017

43

1 reference

15 August 2017

8

1 reference

15 August 2017

1060-1068

1 reference

Comparison of caspofungin and amphotericin B for invasive candidiasis

15 August 2017

1 reference

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

21 January 2018

1 reference

A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan

21 January 2018

1 reference

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

21 January 2018

1 reference

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

21 January 2018

1 reference

Voriconazole salvage treatment of invasive candidiasis.

21 January 2018

1 reference

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

21 January 2018

1 reference

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

21 January 2018

1 reference

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

21 January 2018

1 reference

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.

21 January 2018

1 reference

Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent

21 January 2018

1 reference

A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients

21 January 2018

1 reference

A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

21 January 2018

1 reference

Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin

21 January 2018

1 reference

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

21 January 2018

1 reference

Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases

21 January 2018

1 reference

Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study

21 January 2018

1 reference

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

21 January 2018

1 reference

Combination antifungal therapy for invasive aspergillosis

21 January 2018

1 reference

Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies

21 January 2018

1 reference

Activity of posaconazole in the treatment of central nervous system fungal infections

21 January 2018

1 reference

Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.

21 January 2018

1 reference

Posaconazole as salvage therapy for zygomycosis

21 January 2018

1 reference

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

21 January 2018

1 reference

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

21 January 2018

1 reference

Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever

21 January 2018

1 reference

Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation

21 January 2018

1 reference

Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection

21 January 2018

1 reference

Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/507891

1 reference

15 August 2017

1 reference

PubMed ID

16983621